華媒控股(000607.SZ):控股股東擬增持4000-8000萬元公司股份
格隆匯2月23日丨華媒控股(000607.SZ)公佈,公司於2024年2月23日收到控股股東杭州日報報業集團有限公司《關於增持華媒控股股份及後續增持計劃的吿知函》,杭報集團公司於2024年2月23日通過深圳證券交易所交易系統以集中競價交易方式增持公司股份619,672股。基於對公司未來持續穩定發展的信心以及公司價值的認可,提升投資者信心,杭報集團公司計劃自2024年2月23日起6個月內,在不高於4.2元/股的價格前提下,通過深圳證券交易所交易系統以集中競價交易、大宗交易方式增持公司股份,增持金額4,000—8,000萬元(含2024年2月23日增持金額)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.